Association between anti-thymocyte globulin exposure and clinical outcomes of adult undergoing haploidentical hematopoietic stem cell transplantation with myeloablative conditioning: a pharmacokinetic-guided study.
Abstract
Background
Rabbit antithymocyte globulin (rATG) plays a critical role in preventing graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). However, conventional weight-based dosing results in substantial interpatient variability in active rATG exposure, potentially affecting transplant outcomes. Defining an optimal exposure range may improve the balance between GVHD prevention and post-transplant survival.
Objective
To characterize active rATG exposure and identify a candidate optimal exposure range associated with improved survival and reduced GVHD in patients with acute leukemia undergoing haplo-HSCT. STUDY
Design
This retrospective, single-center study included 119 patients with acute leukemia who underwent haplo-HSCT between June 2020 and March 2023. Active rATG concentrations were measured using flow cytometry in 1,919 blood samples, and exposure was quantified as the area under the concentration-time curve (AUC). Restricted cubic spline (RCS) analyses were performed to explore exposure-outcome relationships. Clinical outcomes were compared across exposure groups, and Cox proportional hazards regression was used to identify prognostic factors.
Results
RCS analyses revealed significant nonlinear associations between post-HSCT rATG exposure and overall survival (OS; P for nonlinearity =0.018) and grade II-IV acute GVHD (aGVHD; P for nonlinearity = 0.006), supporting a candidate optimal AUC range of 52-78 AU/mL/day. Patients were stratified into low- (<52 AU/mL/day; n=17), optimal- (52-78 AU/mL/day; n=48), and high-exposure (>78 AU/mL/day; n=54) groups. The 2-year OS rates were 58.8%, 91.5%, and 72.1%, respectively (P=0.009), while leukemia-free survival (LFS) rates were 58.8%, 87.2%, and 66.7% (P=0.019). Corresponding GVHD-free/relapse-free survival rates were 29.4%, 74.5%, and 53.7% (P < 0.001). The 100-day cumulative incidence of grade II-IV aGVHD was significantly lower in the optimal-exposure group (16.7%) than in the low- (52.9%) and high-exposure (31.5%) groups (overall P=0.012). No statistically significant differences in cytomegalovirus or Epstein-Barr virus reactivation were observed among groups (P=0.519 and P=0.068, respectively). Multivariable Cox regression confirmed a significant association between post-HSCT rATG exposure and OS (overall P=0.035). Compared with optimal exposure, low exposure was associated with a significantly increased mortality risk (hazard ratio=4.81, 95% confidence interval: 1.45-16.01, P = 0.010).
Conclusion
In adults with acute leukemia undergoing ATG-based myeloablative haplo-HSCT, a post-transplant active rATG AUC of 52-78 AU/mL/day was associated with favorable survival outcomes and reduced aGVHD incidence, without increasing viral reactivation risks. These findings support further development of pharmacokinetic-guided ATG dosing strategies, although prospective external validation across different transplant platforms, conditioning regimens, and graft sources is required.